Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.
Yemen Cholera Outbreak October 2026: Alarming Surge
Yemen cholera outbreak October 2026: WHO says suspected weekly cases tripled in three weeks. Figures are suspected, not lab-confirmed.
Sahajanand Medical Technologies IPO: Price Band ₹327-344
Sahajanand Medical Technologies IPO opens 15 October at ₹327-344. It is entirely an offer for sale, so the company receives no proceeds.
Hospital Treatment Charges India 2026: Display Rules
Hospital treatment charges India 2026: the Centre asks states to ensure rates are displayed prominently. It restates existing law and sets no price cap.
Camcevi China Approval 2026: 6-Month Prostate Drug
Camcevi China approval 2026: the NMPA clears a six-month leuprolide injection for advanced prostate cancer. A Chinese decision, not a new FDA one.
Regeneron Pasatru Phase 3 Results: No New FOP Lesions
Regeneron Pasatru Phase 3 results: no new FOP bone lesions from weeks 56 to 84 versus nine on placebo. Already approved; infections rose with dose.
Eli Lilly Prelude Breast Cancer Trial: PRT13722 Phase 1
Eli Lilly Prelude breast cancer trial: Lilly will supply two drugs for a Phase 1 study of PRT13722. Enrolment is due in Q4 2026; no human data yet.
Pfizer Enodia Therapeutics Deal: $500M+ Sec61 Pact
Pfizer Enodia Therapeutics deal: a Sec61 inhibitor collaboration worth over $500M in potential value. Upfront undisclosed; discovery stage only.
BioNTech mRNA Cancer Therapy Trial: BNT113 Misses PFS Goal
BioNTech mRNA cancer therapy trial: BNT113 missed the PFS endpoint in AHEAD-MERIT, but the study continues to an overall survival analysis.
Pennsylvania Measles Outbreak October 2026: Coroner Report
Pennsylvania measles outbreak October 2026: a coroner reports a sixth death; the state has confirmed five and is reviewing. Latest cases and advice.
Translumina SPARX Clinical Trial: 1,380-Patient DCB Study
Translumina SPARX clinical trial: 1,380 patients, 10 countries, drug-coated balloons versus stents. The trial has just started, so no results yet.